William Keogh
Hematology & Oncology · Upland, PANPI 1205827730
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.7% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 9.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,980 and has fallen 84.6% since, to $306 in 2022.
Across 156 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$340
- Johnson & Johnson$298
- Bristol Myers Squibb$240
- Genentech USA, Inc.$225
- Merck$210
- E.r. Squibb & Sons, L.L.C.$203
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,16291%
- Education$3249%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 10 | $340 |
| Johnson & Johnson(2 entities) | 13 | $298 |
| Bristol Myers Squibb | 8 | $240 |
| Genentech USA, Inc. | 9 | $225 |
| Merck | 15 | $210 |
| E.r. Squibb & Sons, L.L.C. | 12 | $203 |
| Amgen | 10 | $202 |
| Gilead(2 entities) | 7 | $180 |
| Verastem, Inc. | 2 | $151 |
| Seagen Inc. | 3 | $140 |
| Novartis | 7 | $133 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $95 |
| AstraZeneca | 3 | $94 |
| EMD Serono, Inc. | 1 | $84 |
| Astellas Pharma US Inc | 4 | $82 |
| Eisai Inc. | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Kyowa Kirin, Inc. | 3 | $53 |
| Taiho Oncology, Inc. | 3 | $53 |
| Daiichi Sankyo Inc. | 3 | $47 |
| AbbVie | 3 | $46 |
| Karyopharm Therapeutics Inc. | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Mylan Institutional Inc. | 2 | $42 |
| Tersera Therapeutics LLC | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Bayer | 2 | $33 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Pfizer | 2 | $24 |
| Dova Pharmaceuticals | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| GE HealthCare | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Array Biopharma Inc | 1 | $18 |
| Clovis Oncology, Inc. | 1 | $17 |
| Exelixis Inc. | 1 | $15 |
| Coherus Oncology, Inc. | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Tesaro, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Copiktra$128
How this compares
$3,486 in reported general payments places this provider in the 60th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Upland
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.